Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, announces a new agreement with Eli Lilly and Company. The partnership will allow the integration of Lilly’s insulin products into Bigfoot’s systems currently in development. (January 7, 2019)